Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
<strong>IMS</strong> COM PANY PRO FILES NOVARTIS<br />
Product Class Date Terms of Agreement<br />
PI 2301 N 2009 Peptimmune granted Novartis an exclusive option to<br />
exclusive worldwide development and commercialization<br />
rights. If Novartis chooses to exercise this option, it<br />
would assume responsibility for the clinical development,<br />
manufacturing and marketing of the agent globally, and<br />
all associated expenses. Novartis would make payments<br />
to Peptimmune (could be in excess of $500 m) upon<br />
exercising the option and achievement of certain<br />
development, regulatory and commercial milestones.<br />
Novartis would also pay royalties on product sales to<br />
Peptimmune. PI 2301 is in development for use in MS.<br />
CMV and RSV vaccines J 2008 AlphaVax granted Novartis an exclusive license to a<br />
cytomegalovirus (CMV) vaccine. The deal also gives<br />
Novartis rights of first negotiation to AlphaVax’s<br />
preclinical respiratory syncytial virus (RSV) program.<br />
HCD 122 L 2008 Restructured agreement between Novartis and XOMA for<br />
HCD 122 and five other projects. Novartis will make an<br />
upfront payment of $6.2m; fully fund all future R&D<br />
expenses; pay potential milestones of up to $14m and<br />
double-digit royalty rates for two programs, including<br />
HCD 122; and provide XOMA with options to develop or<br />
receive royalties on four additional programs that are<br />
pending selection. HCD 122 derives from an original 2004<br />
agreement between Chiron and XOMA to develop<br />
multiple antibody products to treat cancer.<br />
vaccine, influenza,<br />
Dynavax<br />
J 2008 Dynavax signed an agreement with Novartis Vaccines<br />
and Diagnostics for the development, and possible<br />
commercialization of Dynavax’s universal influenza<br />
vaccine.<br />
BA 058 M 2007 An option to obtain an exclusive worldwide license to<br />
develop and commercialize Radius’ osteoporosis drug<br />
candidate.<br />
Nicotine-Qbeta (vaccine,<br />
nicotine withdrawal,<br />
Cytos)<br />
N 2007 Licensed-in from Cytos for markets worldwide.<br />
Vaccines J 2007 Alliance with Intercell relating to the development of a<br />
number of vaccines for infectious diseases. Novartis<br />
gained rights to Group B Streptococcus vaccine program<br />
in December 2008.<br />
ASA 404 L 2007 Licensed-in from Antisoma for global markets.<br />
© 2009 <strong>IMS</strong> Health In cor po rated or its af fil i ates Page 127
Change language